The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 01, 2025

Filed:

May. 18, 2021
Applicant:

Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);

Inventors:

Esteban Masuda, Menlo Park, CA (US);

Vadim Markovtsov, San Mateo, CA (US);

Assignee:

Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5383 (2006.01); A61K 31/155 (2006.01); A61K 31/245 (2006.01); A61K 31/427 (2006.01); A61K 31/4706 (2006.01); A61K 31/4748 (2006.01); A61K 31/519 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 31/7048 (2006.01); A61K 39/42 (2006.01); A61P 31/14 (2006.01); C07K 16/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/155 (2013.01); A61K 31/245 (2013.01); A61K 31/427 (2013.01); A61K 31/4706 (2013.01); A61K 31/4748 (2013.01); A61K 31/519 (2013.01); A61K 31/573 (2013.01); A61K 31/7048 (2013.01); A61K 39/42 (2013.01); A61P 31/14 (2018.01); C07K 16/1003 (2023.08);
Abstract

Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.


Find Patent Forward Citations

Loading…